15q13-15 Rearrangements

Nyla A Heerema

The Ohio State University Medical Center, Department of Pathology, Columbus, Ohio, USA (NAH)

Published in Atlas Database: September 2003
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/15q13rearID1257.html
DOI: 10.4267/2042/38027
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2003 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

Disease
Acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CML), chronic lymphocytic leukemia (CLL) and non Hodgkin lymphomas (NHL).

Phenotype/cell stem origin
Most ALL are B-lineage, few T-lineage.
AML: most subtypes.
CML: Lymphomas: described in follicular, diffuse large B-cell, mantle cell and anaplastic large cell, as well as Hodgkin lymphomas.

Epidemiology
Rare in childhood ALL (about 1%), more common in infant ALL (about 13%).
Very rare in AML, adult ALL, CLL and lympho-mas. Occurs in primary and secondary leukemias.
CML: rare, occurs as secondary abnormality or part of complex Ph rearrangement.

Prognosis
Childhood ALL: No increased risk with current treatment regimens. Outcome not described in other diseases.

Cytogenetics

Additional anomalies
Various anomalies result in 15q13-15 breakpoints, most frequently balanced translocations, but also unbalanced translocations and deletions.
Childhood ALL: 15q13-15 breakpoints frequently occur in complex karyotypes. Associated abnormalities of 9p and of 12p 12p, as well as t(9;22)(q34;q11.2) are common. 15q13-15 break-points also have been reported with der(19)t(1;19)(q21;q13). A t(5;15)(p15.1 or p15.3;q11 or q13) occurs primarily in infant ALL, although also was reported in one adolescent ALL.
AML: found as primary abnormality and as secondary abnormality, with various other abnormalities including t(9;22)(q34;q11.2), t(8;21)(q22;q22), as well as part of complex rearrangements with 8q22 and 21q22. Recurrent aberrations are: t(11;15)(q23;q14) reported in both AML and ALL and t(12;15)(p12-13;q13-15) in AML.
CML: occurs in variant Ph and in secondary abnormalities.

References

This article should be referenced as such: